Sedana Medical AB’s Interim report January-June 2023
Strong sales momentum and a clear target to achieve EBITDA break-even in our Ex-US business during 2024Second quarter 2023 · Net sales for the quarter totalled MSEK 37.3 (26.9), equivalent to an increase of 39% compared to the same quarter 2022. At constant exchange rates, sales increased by 27%. · Gross profit was MSEK 26.6 (18.9) equivalent to a margin of 71% (70%). · Earnings before interest, taxes, depreciation and amortisation (EBITDA) totalled MSEK -10.7 (-23.9), equivalent to an EBITDA margin of -29% (-89%). · Operating income (EBIT) totalled MSEK -16.3 (-29.8),